Compare Enveric Biosciences Inc (ENVB) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Nomura Holdings Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Nomura Holdings Inc trades at $9.49 (market cap $27.55B). The key difference: Nomura Holdings Inc is far larger — about 4051.5× Enveric Biosciences Inc's market cap, and Nomura Holdings Inc pays a 3.4% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Nomura Holdings Inc for 55 Days on average.
| ENVB | NMR | |
|---|---|---|
Market Cap | $6.80M | $27.55B |
Volume | 64,867 | 782,470 |
Sector | Health | Financials |
52-Week High | $10.80 | $10.86 |
52-Week Low | $1.27 | $6.73 |
Typical Hold Time | 14 Days | 55 Days |
Enterprise Value | -$1.49M | $38.54T |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Nomura Holdings (NMR) trades at $9.53, down 2.56% today amid bearish technical signals. The stock shows mixed fundamentals with strong revenue growth to $1.66T in 2025 and net income margin of 20.4%, but recent earnings misses and negative operating cash flow raise concerns. Valuation appears reasonable with P/E of 11.29 and P/B of 1.15. Analyst consensus leans cautious with 67% hold ratings despite recent Zacks strong buy recommendations.
NMR presents a value opportunity with attractive valuation multiples, though execution risks persist. The bearish technical trend and inconsistent earnings performance warrant caution. Upside potential exists if the company can sustain revenue growth and improve cash flow generation, but investors should monitor debt levels increasing to 26.25% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
